Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Abuse, PTSD, & Trauma Topic Center

FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
News
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Evi Arthur
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino, Digital Managing Editor
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Tom Valentino, Digital Managing Editor
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network
FDA headquarters
News
FDA Issues Warning Highlighting Risks of Ketamine for Psychiatric Disorder Treatment
10/27/2023
Meagan Thistle
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed...
10/27/2023
Psych Congress Network
News
Second Phase 3 Study of MDMA-Assisted Therapy for PTSD Confirms Findings
09/25/2023
Tom Valentino, Digital Managing Editor
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3...
09/25/2023
Psych Congress Network

Perspectives

Lydia Anne Bartholow
Q&As
Utilizing Trauma-Informed Approaches for Collaborative and Empowering Care
06/02/2023
The latest coverage from Psych Congress Elevate 2023 in Las Vegas, Nevada.
The latest coverage from Psych Congress Elevate 2023 in Las Vegas, Nevada.
The latest coverage from Psych...
06/02/2023
Psych Congress Network
Alana Iglewicz, MD
Q&As
Prioritizing Practical Care When Treating Prologued Grief Disorder
09/17/2022
Over 2 years after the onset of COVID-19, few lives remain untouched by the public health crisis.
Over 2 years after the onset of COVID-19, few lives remain untouched by the public health crisis.
Over 2 years after the onset of...
09/17/2022
Psych Congress Network
Cyrus and Ross
Q&A
Understanding Sociological and Neurobiological Theories Related to Trauma
12/08/2021
In this Q&A, Kali Cyrus, MD, MPH, and Rachel Ross, MD, PhD, elaborate on their Psych Congress 2021 session, “Rethinking Approaches to Trauma for the 21st Century: Underlying Neurobiology and Practical Applications to Big “T” and Little “t”...
In this Q&A, Kali Cyrus, MD, MPH, and Rachel Ross, MD, PhD, elaborate on their Psych Congress 2021 session, “Rethinking Approaches to Trauma for the 21st Century: Underlying Neurobiology and Practical Applications to Big “T” and Little “t”...
In this Q&A, Kali Cyrus, MD,...
12/08/2021
Psych Congress Network
Blog
Preparing for COVID-19-Induced PTSD Among Health Care Providers
04/28/2020
BLOG: Now is the time for us as mental health care providers to begin to prepare ways to reach out to our colleagues on the frontlines to make our services more easily available, starting with the assumption that they are traumatized until...
BLOG: Now is the time for us as mental health care providers to begin to prepare ways to reach out to our colleagues on the frontlines to make our services more easily available, starting with the assumption that they are traumatized until...
BLOG: Now is the time for us as...
04/28/2020
Psych Congress Network
Q&A
Understanding the Damaging Effects of Trauma
02/20/2020
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress...
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress...
Psychiatrist Sarah Vinson, MD,...
02/20/2020
Psych Congress Network
Blog
Watch for our nation`s post-traumatic reactions
09/18/2017
Our nation has been in the eye of two hurricanes—literally and figuratively—punctuated by the exclamation point of the 16th anniversary of 9/11. One way or another, nearly everybody has been affected emotionally.
Our nation has been in the eye of two hurricanes—literally and figuratively—punctuated by the exclamation point of the 16th anniversary of 9/11. One way or another, nearly everybody has been affected emotionally.
Our nation has been in the eye...
09/18/2017
Psych Congress Network
Blog
Vicarious Traumatization in Psychiatrists
10/08/2015
Michael Myers
A recent study of medical students found that 26% of students reported symptoms of vicarious traumatization in their third year of medical school and of these, 50% identified their psychiatry clerkship as the source.
A recent study of medical students found that 26% of students reported symptoms of vicarious traumatization in their third year of medical school and of these, 50% identified their psychiatry clerkship as the source.
A recent study of medical...
10/08/2015
Psych Congress Network
Blog
PTSD in Physicians
09/16/2015
Michael Myers
Dr. Myers shares highlights of his presentation titled “PTSD in Psychiatrists: A Hidden Epidemic.”
Dr. Myers shares highlights of his presentation titled “PTSD in Psychiatrists: A Hidden Epidemic.”
Dr. Myers shares highlights of...
09/16/2015
Psych Congress Network
Blog
Where forgiveness fits in the Charleston tragedy
06/22/2015
There are so many important mental health aspects to discuss within the tragic event at the Charleston Church in South Carolina. Among them are:
There are so many important mental health aspects to discuss within the tragic event at the Charleston Church in South Carolina. Among them are:
There are so many important...
06/22/2015
Psych Congress Network
Blog
Trauma Revisited in Late Life
08/28/2014
Although we often assume that the impact of trauma manifests right away, sometimes it can manifest decades later. This phenomenon was commonly seen in many World War II veterans who first began to experience PTSD symptoms around the time of...
Although we often assume that the impact of trauma manifests right away, sometimes it can manifest decades later. This phenomenon was commonly seen in many World War II veterans who first began to experience PTSD symptoms around the time of...
Although we often assume that...
08/28/2014
Psych Congress Network
Nishi Bhopal, MD
Q&As
Dispelling Common Misconceptions About Sleep Medicine
08/08/2024
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5...
08/08/2024
Psych Congress Network
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
The Importance of Sleep Education for Mental Health Clinicians
07/16/2024
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how...
07/16/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
Social Media Etiquette for Mental Health Clinicians
07/01/2024
Nishi Bhopal, MD, explains how to maintain professionalism while using social media to promote one'e telehealth practice.
Nishi Bhopal, MD, explains how to maintain professionalism while using social media to promote one'e telehealth practice.
Nishi Bhopal, MD, explains how...
07/01/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
Leveraging Social Media to Support Your Practice
06/20/2024
Nishi Bhopal, MD, telehealth practitioner, providers insight into how mental health clinicians can utilize social media to improve patient outcomes and combat misinformation.
Nishi Bhopal, MD, telehealth practitioner, providers insight into how mental health clinicians can utilize social media to improve patient outcomes and combat misinformation.
Nishi Bhopal, MD, telehealth...
06/20/2024
Psych Congress Network
Lenard A. Adler, MD
Q&As
The Role of Telehealth in Rising ADHD Diagnosis Rates
06/07/2024

Featuring Lenard A. Adler, MD

Featuring Lenard A. Adler, MD
With the COVID-19 pandemic, telehealth emerged as a crucial tool, allowing remote patient consultations for safety and accessibility. Some argue it also drove the increase in adult ADHD diagnosis. Psych Congress Network sat down with...
With the COVID-19 pandemic, telehealth emerged as a crucial tool, allowing remote patient consultations for safety and accessibility. Some argue it also drove the increase in adult ADHD diagnosis. Psych Congress Network sat down with...
With the COVID-19 pandemic,...
06/07/2024
Psych Congress Network
Dr Tim Wilens
Q&As
Clearing the Clinical Picture: Navigating Adult ADHD Treatment Amid Comorbidities and Misconceptions
06/03/2024

With Tim Wilens, MD

With Tim Wilens, MD
Join Dr Wilens for a Q&A on diagnosing and treating adult ADHD, prevalent misconceptions and stigmas, and stimulant medications.
Join Dr Wilens for a Q&A on diagnosing and treating adult ADHD, prevalent misconceptions and stigmas, and stimulant medications.
Join Dr Wilens for a Q&A on...
06/03/2024
Psych Congress Network
Dr Meyer
Q&As
Examining Lithium as the Benchmark Mood Stabilizer for Bipolar Disorder Treatment
06/03/2024

Featuring Jonathan Meyer, MD

Featuring Jonathan Meyer, MD
Join us for an insightful Q&A with Jonathan Meyer, MD, while he delves into why lithium is heralded as the gold standard mood stabilizer for patients with bipolar disorder with a history of mania.
Join us for an insightful Q&A with Jonathan Meyer, MD, while he delves into why lithium is heralded as the gold standard mood stabilizer for patients with bipolar disorder with a history of mania.
Join us for an insightful Q&A...
06/03/2024
Psych Congress Network
Sandhya Prashad, MD
Q&As
Unlocking the Power of Ketamine With Sandhya Prashad, MD
05/30/2024

Featuring Sandhya Prashad, MD

Featuring Sandhya Prashad, MD
Sandhya Prashad, MD, discusses ketamine applications for treatment-resistant depression.
Sandhya Prashad, MD, discusses ketamine applications for treatment-resistant depression.
Sandhya Prashad, MD, discusses...
05/30/2024
Psych Congress Network
Lenard A. Adler, MD
Q&As
Helping Patients Navigate the Stimulant Shortage and Other Challenges in Adult ADHD
05/28/2024

Featuring Lenard A. Adler, MD

Featuring Lenard A. Adler, MD
In Part 2 of this interview Lenard A. Adler, MD, explains the root causes behind the stimulant medication shortage as well as non-pharmacological strategies clinicians can share with their Adult ADHD patients.
In Part 2 of this interview Lenard A. Adler, MD, explains the root causes behind the stimulant medication shortage as well as non-pharmacological strategies clinicians can share with their Adult ADHD patients.
In Part 2 of this interview...
05/28/2024
Psych Congress Network

Videos

andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
Samantha Lau
Videos
The Collaborative Care Approach and Future of Mental Health
02/14/2022
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses the role of collaborative care in mental health as well as the future of mental health, especially relating to empowering patients to “know that their voices are supported.”
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses the role of collaborative care in mental health as well as the future of mental health, especially relating to empowering patients to “know that their voices are supported.”
Samantha Lau, MSN, FNP-BC,...
02/14/2022
Psych Congress Network
Samantha Lau
Videos
Unpacking Women’s Mental Health Care and Trauma-Informed Psychotherapy
02/01/2022
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses trauma-informed psychotherapy and how it “impacts someone's mental health, physical health, and relationships.”
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses trauma-informed psychotherapy and how it “impacts someone's mental health, physical health, and relationships.”
Samantha Lau, MSN, FNP-BC,...
02/01/2022
Psych Congress Network
Craig Bryan, PsyD, ABPP
Videos
Creating a Crisis Response Plan for Patients With Suicidal Ideation and Trauma-Related Disorders
01/12/2022
Craig Bryan, PsyD, ABPP discusses creating a tailored crisis response plan that helps patients feel more in control of their mental health as well as building a positive clinician-patient relationship.
Craig Bryan, PsyD, ABPP discusses creating a tailored crisis response plan that helps patients feel more in control of their mental health as well as building a positive clinician-patient relationship.
Craig Bryan, PsyD, ABPP...
01/12/2022
Psych Congress Network
Craig Bryan, PsyD, ABPP
Videos
PTSD Comorbid Conditions and Suicidal Ideation Interventions
01/06/2022
Craig Bryan, PsyD, ABPP, explores clinical signs that help diagnose a patient with post-traumatic stress disorder (PTSD), the common comorbid conditions, and suicidal indications.
Craig Bryan, PsyD, ABPP, explores clinical signs that help diagnose a patient with post-traumatic stress disorder (PTSD), the common comorbid conditions, and suicidal indications.
Craig Bryan, PsyD, ABPP,...
01/06/2022
Psych Congress Network
Dr. Robin Carhart-Harris on the Power of Psychedelics
Videos
Dr. Robin Carhart-Harris on the Power of Psychedelics
07/22/2020
Robin Carhart-Harris, PhD, head of the Centre of Psychedelic Research at Imperial College London in England, discusses the power of psychedelics.
Robin Carhart-Harris, PhD, head of the Centre of Psychedelic Research at Imperial College London in England, discusses the power of psychedelics.
Robin Carhart-Harris, PhD, head...
07/22/2020
Psych Congress Network
Videos
Robin Carhart-Harris, PhD, Discusses Psychedelics at Davos Forum
02/07/2019
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
Psychedelics researcher Robin...
02/07/2019
Psych Congress Network
Videos
Using Psychedelics in Psychotherapy
10/23/2016
Psych Congress Steering Committee members Andrew Penn, RN, MS, NP, CNS, APRN-BC, and Saundra Jain, MA, PsyD, LPC, discuss the latest research on the use of psychedelics with psychotherapy.
Psych Congress Steering Committee members Andrew Penn, RN, MS, NP, CNS, APRN-BC, and Saundra Jain, MA, PsyD, LPC, discuss the latest research on the use of psychedelics with psychotherapy.
Psych Congress Steering...
10/23/2016
Psych Congress Network
Julie Carbray, PhD, APRN
Videos
Can ADHD be properly evaluated and treated via telehealth?
08/06/2024
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray,...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
Unraveling the Diagnosis: Differentiating Between ADHD and Bipolar Disorder
08/06/2024
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN,...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
Updates in Bipolar Disorder Treatment
07/31/2024
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she...
07/31/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Comparing VMAT-2 Inhibitor Options for Tardive Dyskinesia Treatment
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Comparing VMAT-2 Inhibitor Options for Tardive Dyskinesia Treatment
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
hoberg
Videos
Tardive Dyskinesia Refresher: Causes, Identification, and Impact
07/10/2024
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox...
07/10/2024
Psych Congress Network
amber hoberg
Videos
Tardive Dyskinesia Refresher: Causes, Identification, and Impact
07/10/2024
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox...
07/10/2024
Psych Congress Network
Julie Carbray, PhD
Videos
Avoiding Cardiometabolic Symptoms in Conventional Bipolar Disorder Treatment
07/10/2024
In this video, Dr Carbray explores the adverse cardiometabolic effects of conventional treatments, including weight gain, impaired glucose, and elevated cholesterol, and their impact on patient outcomes.
In this video, Dr Carbray explores the adverse cardiometabolic effects of conventional treatments, including weight gain, impaired glucose, and elevated cholesterol, and their impact on patient outcomes.
In this video, Dr Carbray...
07/10/2024
Psych Congress Network
chepke
Videos
Differential Diagnosis of Tardive Dyskinesia and Other Movement Disorders
07/09/2024
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Craig Chepke, MD, DFAPA, shares...
07/09/2024
Psych Congress Network

News

FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
News
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Evi Arthur
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino, Digital Managing Editor
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Tom Valentino, Digital Managing Editor
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network
FDA headquarters
News
FDA Issues Warning Highlighting Risks of Ketamine for Psychiatric Disorder Treatment
10/27/2023
Meagan Thistle
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed...
10/27/2023
Psych Congress Network
News
Second Phase 3 Study of MDMA-Assisted Therapy for PTSD Confirms Findings
09/25/2023
Tom Valentino, Digital Managing Editor
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3...
09/25/2023
Psych Congress Network
stock paperwork
News
Written Exposure Therapy on Par With Prolonged Exposure Therapy for PTSD
09/12/2023
Jolynn Tumolo
Written exposure therapy (WET) was non-inferior to more time-intensive prolonged exposure therapy (PE) in veterans with PTSD, according to findings published in JAMA Psychiatry.
Written exposure therapy (WET) was non-inferior to more time-intensive prolonged exposure therapy (PE) in veterans with PTSD, according to findings published in JAMA Psychiatry.
Written exposure therapy (WET)...
09/12/2023
Psych Congress Network
A health care professional reviews paperwork while sitting at a desk in front of a computer
News
Added Remote Support for Antidepressant Discontinuation Offers Only Small Benefits
08/07/2024
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone...
08/07/2024
Psych Congress Network
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
News
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
08/05/2024
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies...
08/05/2024
Psych Congress Network
nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
A brain puzzle against an orange background
News
Most Patients With Schizophrenia Relapse-Free With Paliperidone Palmitate, Open Label Extension Study Finds
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
Doctor and patient
News
Clinician-Level Differences Significantly Affect MDD Prescribing, Outcomes
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
News
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
07/31/2024
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid...
07/31/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
News
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
07/22/2024
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects,...
07/22/2024
Psych Congress Network

Quizzes

quiz
Quiz
Repeated Ketamine Infusion Shows Improvement for Which Disease State?
06/08/2022
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in what disease state, according to a recent study published in The American Journal of Psychiatry? Take the quiz to find out!
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in what disease state, according to a recent study published in The American Journal of Psychiatry? Take the quiz to find out!
Repeated ketamine infusions over...
06/08/2022
Psych Congress Network
Quiz
Quiz: PTSD Found to Be Associated With Symptoms of Which Disorder?
01/13/2020
A recent study found subthreshold and threshold post-traumatic stress disorder to be associated with symptoms of which disorder?
A recent study found subthreshold and threshold post-traumatic stress disorder to be associated with symptoms of which disorder?
A recent study found...
01/13/2020
Psych Congress Network
quiz
Quiz
What role does norepinephrine play in bipolar disorder symptom presentation?
08/07/2024
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do...
08/07/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Expert Insights Quiz
HIPPA Considerations for Social Media
07/22/2024
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice...
07/22/2024
Psych Congress Network
How many symptoms must be present in order to diagnose adult ADHD?
Quiz
How many symptoms must be present in order to diagnose adult ADHD?
07/17/2024
Challenge your diagnostic knowledge!
Challenge your diagnostic knowledge!
Challenge your diagnostic...
07/17/2024
Psych Congress Network
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
Quiz
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
07/16/2024
Do you remember this insight from Dr Jain?
Do you remember this insight from Dr Jain?
Do you remember this insight...
07/16/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
A cartoon illustration of a brain with two medical professionals standing on either side; one holds up a magnifying glass to the brain
Quiz
Differences in ADHD Symptoms Due to Sex
07/02/2024
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR...
07/02/2024
Psych Congress Network
quiz
Quiz
Which factor is NOT consideration when choosing an antidepressant medication?
06/28/2024
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a...
06/28/2024
Psych Congress Network
quiz
Quiz
Which symptoms of schizophrenia must be present to make a diagnosis?
06/21/2024
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic...
06/21/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
Can stimulant use increase risk of heart damage in young adults with ADHD?
Quiz
Can stimulant use increase risk of heart damage in young adults with ADHD?
06/17/2024
Time for a pop quiz!
Time for a pop quiz!
Time for a pop quiz!
06/17/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement